| HOME >> MEDICINE >> TECHNOLOGY |
Contacts Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.847.7799914.847.764michael.aberman@regeneron.competer.dworkin@regeneron.com
TABLE 1REGENERON PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS (Unaudited)(In thousands)December 31,December 31,20122011ASSETSCash, restricted cash, and marketable securities$
587,511$
810,550Accounts receivable - trade, net593,20728,254Accounts receivable from Sanofi99,91374,781Deferred tax assets 340,156Property, plant, and equipment, net379,940367,955Other assets79,76342,043Total assets$
2,080,490$
1,323,583LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable, accrued expenses, and other liabilities$
118,604$
102,068Deferred revenue259,173300,250Facility lease obligations160,810160,514Convertible senior notes296,518275,019Stockholders' equity1,245,385485,732Total liabilities and stockholders' equity$
2,080,490$
1,323,583
TABLE 2REGENERON PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS (Unaudited)(In thousands, except per share data)Three months endedYear endedDecember 31,December 31,2012201120122011Revenues:Net product sales$
281,471$
29,752$
858,093$
44,686Sanofi collaboration revenue104,77977,032423,814326,609Bayer HealthCare collaboration revenue21,7919,37470,09943,072Technology licensing5,8925,89223,57124,858Contract research and other6699272,9006,599414,602122,9771,378,477445,824Expenses:Research and development181,024129,041625,554529,506Selling, general, and administrative57,73936,349210,755117,261Cost of goods sold30,1692,98984,4554,216268,932168,379920,764650,983Income (loss) from operations145,670(45,402)457,713(205,159)Other income (expense):Investment income3847992,01
'/>"/>
| SOURCE Regeneron Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved |